WellPATH-PREVENT: 자살 생각 또는 시도로 입원한 중년 및 고령자를 위한 모바일 개입
The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).
연구 개요
상세 설명
R61 Phase: In this "proof-of-concept" phase, interventionists will administer 12 weeks of WellPATH-PREVENT in 40 middle-aged and older adults who have been discharged after being hospitalized for suicidal ideation or suicide attempt. The interventionist will help the patient incorporate the appropriate data (i.e., triggers, negative emotions, cognitive reappraisal techniques) into the tablet, train the patients on how to use the tablet, and coach them during the 12 weeks. There will be 4 assessments: At study entry (admission/during hospitalization), hospital discharge, 6, and 12 weeks. An EEG will be conducted upon entry into the study, at Week 6, and at Week 12.
R33 Phase: 75 middle-aged and older adults who have been recently discharged after a hospitalization for suicidal ideation or attempt will be recruited and randomized to an optimized version of WellPATH-PREVENT (Week 6 and Week 12 duration based on R61 results) or to Attention Control-Usual Care with a tablet (AC-UC). There will be 5 assessments: At study entry (admission/during hospitalization), discharge, 6, 12 and 24 weeks. Participants who exit the study prior to completion will be invited to have an assessment before termination as close to the scheduled time point as possible. Psychiatrically re-hospitalized participants will not be dropped from the study but will have an additional assessment and will continue the assessments as scheduled based on their initial hospitalization.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Dimitris Kiosses, PhD
- 전화번호: 914-997-4381
- 이메일: dkiosses@med.cornell.edu
연구 연락처 백업
- 이름: Laurie Evans, MS
- 전화번호: 1012570 914-682-9100
- 이메일: lad9011@med.cornell.edu
연구 장소
-
-
New York
-
New York, New York, 미국, 10065
- 아직 모집하지 않음
- New York Presbyterian Hospital/Weill Cornell Medicine
-
연락하다:
- Dimitris Kiosses, PhD
- 전화번호: 914-997-4381
- 이메일: dkiosses@med.cornell.edu
-
연락하다:
- Laurie Evans, MS
- 전화번호: 1012570 914-682-9100
- 이메일: lad9011@med.cornell.edu
-
White Plains, New York, 미국, 10605
- 모병
- Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine
-
연락하다:
- Dimitris Kiosses, PhD
- 전화번호: 914-997-4381
- 이메일: dkiosses@med.cornell.edu
-
연락하다:
- Laurie Evans, MS
- 전화번호: 1012570 914-682-9100
- 이메일: lad9011@med.cornell.edu
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 50-90 years old
- Diagnosis (based on a modified SCID-5 Clinical Trials Version to assess DSM-5 diagnoses): Any DSM-5 except: current diagnosis of Psychotic Disorder; diagnosis of Dementia
- Recent hospitalization for suicidal ideation or suicide attempt; at hospital admission, Columbia Suicide Severity Rating Scale (CSSR-S) ≥ 2, "Non-specific Active Suicidal Thoughts."
- We will also include patients on psychotropics and on after-care community psychotherapy.
Exclusion Criteria:
- Current diagnosis of Psychotic Disorders; Diagnosis of Dementia
- Cognitive Impairment (MMSE ≤ 24)
- Acute or severe medical illness (i.e., delirium; decompensated cardiac, liver or kidney failure; major surgery; stroke or myocardial infarction during the three months prior to entry
- Aphasia, sensory problems, and/or inability to speak English.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 개념 증명 WellPATH-PREVENT(R61)
|
WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app. |
|
실험적: 최적화된 WellPATH-PREVENT(R33)
|
The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal. |
|
간섭 없음: Attention Control Usual Care (R33)
The AC-UC group will parallel the delivery of the WellPATH-PREVENT intervention and will also include: a) meetings during hospitalization: a non-clinical member of the team will present the control tablet and explain its use; b) scheduled or requested meetings through zoom: to parallel the delivery of WellPATH-PREVENT. The tablet will still have a link to schedule a meeting with a non-clinician member of the team. The meetings will focus on issues that the patient may have in using the tablet. There will not be any therapeutic or psychological interaction between participants in the control group and the team. The experimental and the control group will also be under usual outpatient care, which is arranged during the hospitalization by the inpatient treatment team. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R61
기간: Study Entry, Week 6, Week 12
|
ERP is used to measure the amplitude (magnitude) of electrocortical activity (measured in μV) during an emotion regulation task. |
Study Entry, Week 6, Week 12
|
|
Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R33
기간: Study Entry, Week 6, Week 12, Week 24
|
ERP is used to measure the amplitude (magnitude) of electrocortical activity (measured in μV) during an emotion regulation task. |
Study Entry, Week 6, Week 12, Week 24
|
|
Change in Self-Reported Affect - R61
기간: Study Entry, Week 6, Week 12
|
Self-reported affect is used to study changes in negative emotions during an EEG emotion regulation task. It is based on a participant's rating of negative emotions (Likert scale: 1-5; 5 most negative) during the task. |
Study Entry, Week 6, Week 12
|
|
Change in Self-Reported Affect - R33
기간: Study Entry, Week 6, Week 12, Week 24
|
Self-reported affect is used to study changes in negative emotions during an EEG emotion regulation task. It is based on a participant's rating of negative emotions (Likert scale: 1-5; 5 most negative) during the task. |
Study Entry, Week 6, Week 12, Week 24
|
|
Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R61
기간: Study Entry, Week 6, Week 12
|
ERQ is an interviewer-administered instrument to evaluate cognitive reappraisal ability. Scores can range from 1-7, where higher scores indicate greater use of emotion regulation strategies and lower scores indicate less frequent use of such strategies. |
Study Entry, Week 6, Week 12
|
|
Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R33
기간: Study Entry, Week 6, Week 12, Week 24
|
ERQ is an interviewer-administered instrument to evaluate cognitive reappraisal ability. Scores can range from 1-7, where higher scores indicate greater use of emotion regulation strategies and lower scores indicate less frequent use of such strategies. |
Study Entry, Week 6, Week 12, Week 24
|
|
Change in Client Satisfaction with Treatment (CSQ) - R61
기간: Week 6, Week 12
|
Client Satisfaction Questionnaire is a self-report that measures patient satisfaction with intervention/treatment. Scores can range from 3-12, where higher values indicate higher satisfaction. |
Week 6, Week 12
|
|
Change in Client Satisfaction with Treatment (CSQ) - R33
기간: Week 6, Week 12, Week 24
|
Client Satisfaction Questionnaire is a self-report that measures patient satisfaction with intervention/treatment. Scores can range from 3-12, where higher values indicate higher satisfaction. |
Week 6, Week 12, Week 24
|
|
Change in Suicide Risk - Columbia Suicide Severity Scale (C-SSRS) - R61
기간: Weekly from Study Entry to Week 12 (R61)
|
C-SSRS is used to measure intensity of suicidal ideation. Scores range from 0-5, where higher scores indicate more severe ideation. |
Weekly from Study Entry to Week 12 (R61)
|
|
Change in Suicide Risk - Columbia Suicide Severity Scale (C-SSRS) - R33
기간: Weekly from Study Entry to Week 24
|
C-SSRS is used to measure intensity of suicidal ideation. Scores range from 0-5, where higher scores indicate more severe ideation. |
Weekly from Study Entry to Week 24
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Dimitris Kiosses, PhD, Weill Medical College of Cornell University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 21-12024207
- R61MH128516 (미국 NIH 보조금/계약)
- R33MH128516 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
De-identified data from this study is submitted to the National Database for Clinical Trials related to Mental Illness (NDCT). The NDCT is run by NIH and allows researchers studying mental health to collect and share information with each other. Researchers must apply to NIH in order to be allowed access to the data for 1 year's time; after which they must re-apply.
IPD 공유 기간
Data will be available as per NIH's data sharing policy.
IPD 공유 액세스 기준
Access criteria is determined by NIH and can be requested by applying online.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .